
Novacyt Investor Relations Material
Latest events

H2 2024
Novacyt
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Novacyt S.A.
Access all reports
Novacyt S.A. is a biotechnology company focused on the development, manufacturing, and commercialization of clinical diagnostic products. It operates primarily through its business units, including Primerdesign, Lab21 Products, and IT-IS International. The company specializes in in vitro and molecular diagnostics, offering a wide range of assays, reagents, and PCR devices for detecting various infectious diseases, including pathogens responsible for respiratory, gastrointestinal, and insect-borne illnesses. Novacyt serves a global market, providing its products to public hospitals, central laboratories, and private testing facilities. The company is headquartered in Camberley, United Kingdom, and its shares are listed on the Euronext Growth.
Key slides for Novacyt S.A.


H2 2024
Novacyt S.A.


H1 2024
Novacyt S.A.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ALNOV
Country
🇫🇷 France